CORRELATION OF THROMBUS AREA WITH ANGIOGRAPHIC AND CLINICAL OUTCOMES IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PRIMARY PCI: ANALYSIS FROM THE HORISONS-AMI TRIAL  by He, Yong et al.
A124.E1165
JACC March 9, 2010
Volume 55, issue 10A
 MYOCARDIAL ISCHEMIA AND INFARCTION 
CORRELATION OF THROMBUS AREA WITH ANGIOGRAPHIC AND CLINICAL OUTCOMES IN PATIENTS 
WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PRIMARY PCI: ANALYSIS 
FROM THE HORISONS-AMI TRIAL
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Tuesday, March 16, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Unstable Ischemic Syndrome/Bleeding Issues & Outcome
Abstract Category: Unstable Ischemic Syndrome/Long-Term Outcome
Presentation Number: 1264-268
Authors: Yong He, Eugenia Nikolsky, Alexandra J. Lansky, Roxana Mehran, Adriano Caixeta, George Dangas, LeRoy Rabbani, Gregg W. Stone, 
Cardiovascular Research Foundation and Columbia University Medical Center, New York, NY
Background: Presence of thrombus is known to worsen microvascular perfusion in patients with STEMI undergoing primary PCI. However, impact of 
thrombus burden as assessed by thrombus area on prognosis of patients with STEMI is less certain.
Methods and Results: In the HORIZONS-AMI trial, a total of 2349 pts with single thrombotic lesion on baseline coronary angiogram was 
identified. Outcomes were analyzed in relation to tertiles of thrombus area. Larger thrombus area was associated with male gender, higher BMI, 
higher rates of right coronary artery infarct vessel, bigger vessel reference diameter, longer culprit lesion and stent length, more frequent use of 
thrombus aspiration device, longer fluoroscopy time and larger volume of contrast media (p values from 0.02 to <0.0001). TIMI flow 0/1 was 
significantly more frequent in patients with bigger thrombus area on baseline angiogram (67.2% vs. 79.7% vs. 83.1%, p<0.0001) but not on final 
angiogram (1.9% vs. 2.7% vs. 1.7%, p=0.34). Slow flow/no reflow occurred significantly more frequently with increment in thrombus area (1.8% vs. 
2.1% vs. 3.5%, p=0.005). As shown in the Table, clinical outcomes at 30 days and at 1 year did not differ in relation to thrombus area except for 
higher 1-year incidence of probable/definite stent thrombosis. By multivariable analysis, thrombus area was not associated with ischemic outcomes 
at 30 days or 1 year.
Conclusion: In HORIZONS-AMI trial, thrombus area as measured by angiography did not predict adverse outcomes at follow-up. 
Outcomes, %
Patients with STEMI and evidence of thrombus by angiography (tertiles of thrombus area)
P≤ 21.4 mm2
n=783
>21.4 to ≤ 34.5 mm2
n=783
>34.5 mm2
n=783
At 30 days
Death 1.7% 3.1% 2.7% 0.18
Reinfarction 1.7% 1.9% 1.8% 0.92
Ischemic TVR 1.5% 2.3% 3.1% 0.13
Stroke 0.5% 0.4% 0.3% 0.72
Definite/probable stent thrombosis (ARC) 1.9% 2.7% 3.1% 0.27
Major Bleeding (non-CABG related) 6.5% 6.5% 8.3% 0.28
MACE* 4.1% 5.9% 5.8% 0.21
Net adverse clinical events† 9.2% 10.9% 12.5% 0.10
At 1 year
Death 2.8% 4.2% 4.0% 0.28
Reinfarction 3.4% 4.3% 3.7% 0.69
Ischemic TVR 5.7% 5.9% 8.2% 0.08
Stroke 0.9% 0.8% 0.7% 0.85
Definite stent thrombosis (ARC) 1.3% 3.6% 3.7% 0.01
Definite/probable stent thrombosis (ARC) 2.0% 4.1% 4.4% 0.027
Major Bleeding (non-CABG related) 6.9% 7.1% 8.9% 0.25
MACE 10.2% 12.0% 12.1% 0.40
Net adverse clinical events† 14.6% 16.4% 18.2% 0.17
*Death, reinfarction, ischemic target vessel revascularization (TVR) or stroke
†MACE or protocol defined non-CABG major bleeding
